File A01428 ("Insurers must cover brand drugs during generic shortages") is before the New York Legislature and has not been decided. Latest step (March 19, 2026): advanced to third reading cal.311.
New York file A01428, before the New York Legislature. Still to be decided as of 2026-03-19.
Your insurer covers brand drugs when generics are unavailable If the FDA declares a generic drug in short supply, your insurance plan must cover the brand-name equivalent at the generic copay rate rather than rejecting the prescription or charging you the higher brand copay.
Insurer costs may shift; drug makers face new leverage Insurance companies will bear increased costs during FDA-declared shortages, which may eventually be reflected in premiums, while brand-name manufacturers gain negotiating advantage when generic supply chains fail.
Depends on FDA formally declaring a shortage exists The law only triggers if the FDA has officially declared a supply shortage; informal supply disruptions, price spikes, or delayed deliveries that don't meet the FDA threshold will not obligate coverage of the brand alternative.
Read the official record for A01428
See everything up for a vote · This week in New York · See what we have filed with the clerk